Blinatumomab
- Generic Name
- Blinatumomab
- Brand Names
- Blincyto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 853426-35-4
- Unique Ingredient Identifier
- 4FR53SIF3A
- Background
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...
- Indication
Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...
- Associated Conditions
- Precursor B-lymphoblastic leukaemia acute, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyBiological: BlinatumomabDrug: DasatinibDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideProcedure: Multigated Acquisition ScanProcedure: EchocardiographyDrug: Ponatinib HydrochlorideProcedure: ElectrocardiographyDrug: PrednisoneProcedure: Lumbar PunctureDrug: MethotrexateDrug: MesnaDrug: Vincristine Sulfate
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 348
- Registration Number
- NCT04530565
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 17
- Registration Number
- NCT04524455
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite, France
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Cataluña, Spain
🇩🇪Universitätsklinikum Schleswig-Holstein, Kiel, Germany
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 125
- Registration Number
- NCT04521231
- Locations
- 🇮🇹
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸New York University Grossman School of Medicine and New York University Langone Hospitals, New York, New York, United States
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT04506086
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
- First Posted Date
- 2020-06-26
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Dorothy Sipkins, MD, PhD
- Registration Number
- NCT04448834
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Novant Health Cancer Institute and Innovation Center, Winston-Salem, North Carolina, United States
Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Israeli Medical Association
- Target Recruit Count
- 110
- Registration Number
- NCT04334993
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Shaarei Tzedek Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Mats Heyman
- Target Recruit Count
- 6430
- Registration Number
- NCT04307576
- Locations
- 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Klinikum Bremen Mitte, Bremen, Germany
🇩🇪Universitätsmedizin Mainz, Mainz, Germany
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04260022
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸City of Hope, Duarte, California, United States
BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 41
- Registration Number
- NCT03931642
- Locations
- 🇫🇷
Chu Amiens, Amiens, France
🇫🇷Hôpital Avicenne - Centre de Recherche Clinique, Bobigny, France
🇫🇷CH de Béziers - Hématologie, Béziers, France
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Asparaginase Erwinia chrysanthemiDrug: CyclophosphamideBiological: BlinatumomabDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: Mercaptopurine Oral SuspensionDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: PrednisoloneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6720
- Registration Number
- NCT03914625
- Locations
- 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.